• Neslihan Kayahan, Mustafa Karaca, Hasan Satış, Dilek Yapar, and Ahmet Özet.
• Department of Internal Medicine Sciences, Faculty of Medicine, Gülhane Research and Training Hospital, Ankara, Turkey
• Turk J Med Sci. 2021 Aug 30; 51 (4): 172717321727-1732.

Background/AimThe purpose of this study was to compare efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine-cisplatin as first-line therapy in patients with pancreatic cancer.Materials And MethodsPancreaticobiliary cancer patients who had Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating greater severity of illness) were evaluated to receive folfirinox or gemcitabine plus cisplatin. The primary endpoints were progression-free and overall survival time. Safety analysis was also evaluated as secondary measures.ResultsThere were 32 patients in the folfirinox group and 36 patients in the gemcitabine-cisplatin group. The median overall survival was 18.1 months (7.5–28.7) in the folfirinox group as compared with 9.7 months (6.5–13) in the gemcitabine-cisplatin group (p = 0.009). Median progression-free survival was 16.2 months (9–23.4) in the folfirinox group and 6.9 months (6.1–7.6) in the gemcitabine- cisplatin group (p = 0.001).ConclusionFolfirinox is an option for the first-line treatment of patients with pancreatic cancer and good performance status.This work is licensed under a Creative Commons Attribution 4.0 International License.

37 keywords...

hide…